



Building Back Better Post-Pandemic

Thursday 12 May 2022, Hilton DoubleTree Tower Bridge, London

<https://cancerforum.hsj.co.uk/>

DRAFT AGENDA	
08.15 – 09.15	Registration & refreshments
09.15 – 09.25	Opening remarks from the chair <i>Alastair McLellan, Editor, HSJ</i>
09.25 – 09.55	Keynote: Delivering the NHS Long Term Plan cancer ambitions <ul style="list-style-type: none">• Completing the task of recovery from the impacts of the pandemic and rising to the challenge of record high levels of referrals• Improving operational performance through expanding capacity and new faster diagnosis initiatives• Accelerating progress on our earlier diagnosis ambition through a multi-faceted approach• Putting patient experience at the heart of what we do <i>Liz Bishop, Chief Executive, The Clatterbridge Cancer Centre NHS Foundation Trust & SRO, Cheshire & Merseyside Cancer Alliance, & Member, National Cancer Board, NHS England</i>

<p>09.55 – 10.35</p>	<p>Panel: Rising to the challenge of a post pandemic recovery</p> <ul style="list-style-type: none"> • Adopting a ‘whole system’ thinking encompassing new treatments for better outcomes, reduce toxicity, and simplifying administration • What has the Covid pandemic taught us about collaboration? How do we embed this in practice? • Leveraging advances in telemedicine and remote consultations • Artificial intelligence and wearables for remote patient monitoring to deliver patient convenience and service efficiencies • Expanding drive through services and self-administered treatments at home • How more tolerable treatments (oral and subcutaneous delivery) can increase throughput, ease capacity issues, and improve the patient experience • What’s the latest thinking about the risks of surgery where patients have had Covid? <p><i>Moderator: Alastair McLellan, Editor, HSJ</i></p> <p><i>Panellists:</i></p> <p>Roland Kreissig, General Manager, Oncology UK & Ireland, Novartis</p> <p>Liz Bishop, Chief Executive, The Clatterbridge Cancer Centre NHS Foundation Trust & SRO, Cheshire & Merseyside Cancer Alliance, & Member, National Cancer Board, NHS England</p> <p>Lynda Thomas, Chief Executive, Macmillan Cancer Support</p> <p>Geoff Bellingan, Medical Director, Cancer & Surgery Board, UCLH</p>
<p>10.35 – 11.00</p>	<p>Morning break for refreshments & networking</p>
<p>11.00 – 12.05</p>	<p>Interactive Discussion Groups</p> <p><i>Interactive roundtable discussions, each 25 mins duration, so attendees can choose 2 of the following topics:</i></p> <ol style="list-style-type: none"> 1. Innovative payment models to unlock new cancer treatments for patients <i>Is it time for more innovative outcomes-based payment models to ensure faster and broader patient access to new cancer drugs? Industry, healthcare providers, professionals and patient organisations have a shared agenda to ensure that new licensed innovations in rare, less common and challenging cancer treatment areas reach all suitable patients as quickly as possible. One major barrier is how innovation is incentivised and appropriately valued. The UK has a strong track record on early access through the Cancer Drugs Fund but the high level of conditional approvals could reflect gaps in data or an unwillingness to embrace new thinking in assessment and payment models. Our discussion will centre on collaborating in evidence generation and exploring what could be the most effective payment models, such as outcomes-based schemes, which could see the NHS as the destination for full and fast access and uptake, resulting in much improved patient benefits.</i> <i>Moderators: Jack Harris, VP & Head of UK Oncology & John Lynes, UK Director of Gynaecological Oncology Medical Affairs, GSK</i> 2. Good quality, personalised care – who’s falling through the gaps and how do we reach them? <i>The evidence shows that there is significant variation in people with cancer receiving good quality personalised care, so tackling inequalities must be our priority. We know from the National Cancer Patient Experience Survey that people from some ethnically diverse groups report worse experiences of care - and these inequalities are likely to have worsened during the pandemic. This variation isn’t acceptable. Much is</i>

	<p><i>riding on the Government's forthcoming 10-year National Cancer Plan, but in the meantime - what is the system doing to address the inequalities that exist, and what are you doing in your services?</i> Moderators: Emma Tingley, Head of Partnerships & Zoe Kabir, Head of Operational Support, Macmillan Cancer Support</p> <p>3. AI technologies to revolutionise cancer care <i>Artificial Intelligence (AI) is a buzz word in cancer care. But what does it actually mean? How can we differentiate the real problems at hand from the fiction that's floating around? This session will look to co-create a real problem to fix as a starting point for the advancement of prediction, automation and patient care.</i> Moderator: Konrad Dobschuetz, Head of Customer Solutions, Digital & Health Innovation & Lead, BIOME UK, Novartis</p> <p>4. System readiness for cell therapies Moderator: Anita Ralli, Associate Director of Government Affairs, Gilead Sciences</p> <p>5. Can data alleviate the cancer workforce crisis? Moderators: Chris Thomas, Head of the Commission on Health & Prosperity, Institute for Public Policy Research (IPPR) & Chris Lowry, Public Affairs Manager, Eli Lilly</p> <p>6. Breast cancer and the 10 year plan <i>This interactive discussion will focus on what needs to happen to improve breast cancer diagnosis, treatment and care with an opportunity to share examples of success and best practice. We'll cover topical issues such as the workforce crisis, the impact of the pandemic on early diagnosis and meeting the needs of people living with secondary (metastatic) breast cancer.</i> Moderator: Baroness Delyth Morgan, Chief Executive, Breast Cancer Now</p>
12.05 – 12.10	Transition
12.10 – 12.50	<p>Panel: Tackling inequality in cancer care and treatment</p> <ul style="list-style-type: none"> • What is the patient experience? And the relationship between patient and care giver? • Equality of voice, and the input from frequently ignored communities/patient groups • Digital inequality as Covid prompted more digital and remote consultations • Improving access to services, and the ability to self-manage • How do we allocate resources optimally to address these inequalities in care and treatment? <p>Moderator: Véronique Walsh, General Manager, UK & Ireland & Vice President, Gilead Sciences Panellists: Majid Kazmi, Director, Cancer & Surgery Group & Deputy Medical Director, Guy's & St Thomas' NHS Foundation Trust Michelle Mitchell, Chief Executive, Cancer Research UK Stewart O'Callaghan, Founder & Chief Executive, Live Through This</p>

	Georgette Oni, Consultant Oncoplastic Surgeon, Nottingham University Hospitals NHS Trust & Trustee, Breast Cancer Now	
12.50 – 13.50	Lunch	
13.50 – 14.30	<p>Panel: Making community diagnostics work</p> <ul style="list-style-type: none"> • Building multi-disciplinary teams and nurse-led services • Supporting the separation of acute and elective diagnostics, providing capacity away from the hospital setting • Managing the community diagnostics workforce effectively • Leveraging digital technologies to optimise efficiency and administration • Pathway redesign and standards for rapid diagnostic services <p><i>Moderator: Alastair McLellan, Editor, HSJ</i></p> <p><i>Panellists:</i></p> <p>Roger Prudham, Clinical Director, Northern Care Alliance Ian Francis, Deputy Medical Director & Clinical Director for Cancer & Surgery, Queen Victoria Hospital NHS Foundation Trust Michaela Golodnitski, Programme Lead - Diagnostics, Humber, Coast & Vale Cancer Alliance Matt Gibson, Head of Diagnostic Imaging, Siemens</p>	
14.30 – 15.10	<p>Panel: How Cancer Alliances are improving care, services and outcomes</p> <ul style="list-style-type: none"> • Stakeholders, governance, accountability, and transparency • Benefits of local and ‘place-based’ planning for cancer care and diagnostics • How useful are the alliances from a national programme perspective? • How do alliances tackle inequalities both between and within alliances? • How do alliances develop and spread innovation between and within alliances? <p><i>Moderator: Alastair McLellan, Editor, HSJ</i></p> <p><i>Panellists:</i></p> <p>David Shackley, Medical Director, Greater Manchester Cancer & Clinical Lead, Manchester Academic Health Science Centre (MAHSC) & Consultant, Salford Royal NHS Foundation Trust Amanda Pleavin, Managing Director, East of England Cancer Alliance Amelia Randle, Clinical Chair, Somerset, Wiltshire, Avon & Gloucestershire Cancer Alliance Ian Vousden, Programme Director, Kent & Medway Cancer Alliance, NHSE/I South East</p>	
15.10 – 15.35	Afternoon break for refreshments & networks	
	Chair: Giles Maskell, Consultant Radiologist, Royal Cornwall Hospitals NHS Trust	Chair: Ben Clover, Bureau Chief, HSJ

<p>15.35 – 16.00</p>	<p>How Cheshire & Merseyside Radiology Imaging Network (CAMRIN) is developing Rapid Diagnostics Services (RDS)</p> <ul style="list-style-type: none"> • Reviewing cancer imaging across the network • Optimising pathways and protocols • Integrating education and training where required • What results are we seeing so far? <p><i>David White, Clinical Lead, Cheshire & Merseyside Imaging Network</i></p>	<p>Advances in lung cancer care and treatment: Stereotactic ablative radiotherapy (SABR)</p> <ul style="list-style-type: none"> • Improving outcomes and the patient experience • Optimising the SABR patient pathway • Ensuring equitable access to SABR for lung cancer • Implications for SABR in the NHS Long Term Plan <p><i>Neil Bayman, Consultant Clinical Oncologist & Medical Director, The Christie NHS Foundation Trust</i></p>
<p>16.00 – 16.05</p>	<p>Transition</p>	
<p>16.05 – 16.30</p>	<p>Combining breast cancer surgery with radiotherapy</p> <ul style="list-style-type: none"> • Getting it Right First Time • What does it mean for patient outcomes? • Optimising the use of your resources • Reducing unnecessary hospital visits and minimising unnecessary interventions <p><i>Jayant Vaidya, Professor of Surgery & Oncology, University College Hospitals NHS Foundation Trust</i></p>	<p>Cancer susceptibility genetics for risk stratification to inform cancer prevention and early detection</p> <p>Identification of individuals at elevated risk of cancer enables us to target resources for screening and early detection to those in who the impact will be greatest. Prof Turnbull will discuss the role of cancer susceptibility genetics, including polygenic risk scores, for cancer risk stratification, with the aim of improving resource use in early detection and prevention.</p> <p><i>Clare Turnbull, Professional of Translational Cancer Genetics, Institute of Cancer Research & Consultant in Clinical Cancer Genetics, Royal Marsden NHS Foundation Trust</i></p>
<p>16.30 – 16.35</p>	<p>Transition</p>	
<p>16.35 – 17.15</p>	<p>Closing Panel: Building the cancer workforce, for now and the future</p> <ul style="list-style-type: none"> • What does Health Education England say about the cancer workforce plan? • Growing and retaining the future cancer workforce - developing cancer career and education frameworks, educational opportunities and new routes to cancer careers • Building the skills, knowledge and expertise of your staff to effectively support people with cancer • Increasing capacity through international recruitment • Exploring approaches to improve staff recruitment and retention • How might the work done by the National Breast Imaging Academy be replicated in other areas? <p><i>Moderator: Alastair McLellan, Editor, HSJ</i></p> <p><i>Panellists:</i></p> <p><i>June Davis, Allied Health Professional Advisor, Macmillan Cancer Support</i></p> <p><i>Laura Steele, President & General Manager, UK, Republic of Ireland & Northern Europe, Eli Lilly & Company</i></p>	

	<i>Mary Wilson, Consultant Breast Radiologist, Manchester University NHS Foundation Trust & Clinical Lead, National Breast Imaging Academy</i> <i>Phil Carver, Director, Health Education England</i>
17.15 – 17.20	Closing remarks from the chair